Insider Peter Svennilson purchased 800,000 shares of Immune Design (IMDZ, Financial) on Sept. 19 at $6.25 per share, according to a Form 4Â filing for the Securities and Exchange Commission.
Since the trade, Immune Design’s market price has gained an estimated 21.28%.
Immune Design Corp. has a market cap of $152.94 million, an enterprise value of $52.11 million, a price-book (P/B) ratio of 1.76, a current ratio of 17.61 and a quick ratio of 17.49.
Immune Design Corp. is a clinical-stage immunotherapy company. The company is focused in oncology and engineers its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer. Immune Design Corp believes that its approach to fighting cancer "is the first of its kind," Â according to the company’s most recent 10-K filing. Immune Design's main focus is immuno-oncology, however, the company believes that some of its platforms also have therapeutic potential in infectious and allergic diseases.
Below is a pipeline of Immune Design’s products, including its Immuno-Oncology Pipeline and its GLAAS Infectious & Allergic Diseases Immunotherapy Pipeline.
According to GuruFocus, Immune Design has a 9 of 10 financial strength rating with no debt. The company also has an equity to asset ratio of 0.89, which ranks it higher than 80% of the 707 companies in the global biotechnology industry. Immune Design also has a 4 of 10 profitability and growth rating with an operating margin of -530.85%, a net-margin of -525.30%, a ROE of -42.79% and a ROA of -40.06%, ranking it beneath 61% of the 966 companies in the global biotechnology industry.
Below is a Peter Lynch chart that shows that Immune Design is trading below its intrinsic value.
Peter Svennilson has served as a board member at Immune Design since 2013. He has also served as a board member at Seragon Pharmaceuticals and NGM Biopharmaceuticals. He was the chairman of the board at Aragon Pharmaceuticals before it was acquired by Johnson & Johnson (JNJ, Financial) in August 2013, and he was also a board member of PTC Therapeutics (PTCT, Financial) from September 2010 Â to March 2013. From 1996 to 2006, Svennilson served as a board member of numerous biotech companies, including Rosetta Informatics, PTC Therapeutics, ChemoCentryx (CCXI, Financial) and Somalogic.
Disclosure:Â Author does not own any shares of this company.
Start a free 7-day trial of Premium Membership to GuruFocus.
